BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NEXTVAL Receives $500,000 SBIR Phase II Grant


5/9/2012 9:15:29 AM

May 09, 2012 -- Nextval, a San Diego based high-throughput bioanalytical technology company, has received an SBIR Phase II grant to further develop and commercialize a groundbreaking technology for high-throughput, cost-effective screening and analysis. Nextval’s new high-throughput screening system is a novel integration of a nanoliter volume acoustic dispense device* with chip-based mass spectrometry. This system produces high-density microarrays that are analyzed with mass spectrometry imaging and computational algorithms. This technology fills the gap between routine generation of high-diversity chemical libraries with molecular genetics and combinatorial chemistry approaches, and the ability to rapidly screen those libraries for high-value molecules.

Phase II efforts will focus on a high-throughput screening product for cellulase enzyme discovery, a critical enzyme in the production of alternative fuels. Currently, screens are limited by traditional optically based detection systems that may generate false leads. Nextval’s integrated high-throughput platform does not require sample labeling, is applicable to a broad range of chemical activities, and provides much more information from a single readout than current approaches. Phase II development will produce a commercial screening technology with these advantages while maintaining the flexibility for future applications. Analysis throughput using this technology is estimated at 250,000 samples per week.

According to Dr. Matthew Greving, Nextval co-founder, the broader impact and commercial potential of this project are cost-effective high-throughput discovery of new enzymes and molecules with enhanced or novel activities in the industrial, environmental, pharmaceutical or diagnostic markets. The proposed technology enables entirely new types of high-throughput screens that are currently inaccessible with existing technologies. Additional plans for Phase II development beyond the alternative fuels market will be a flexible discovery platform that will be applicable to a number of commercial markets.

*Acoustic dispensing provided by EDC/ BioSero

For additional information please contact:

Tom Gilman

Director of Business Development

Nextval, INC

4186 Sorrento Valley Blvd, Suite G

San Diego, CA 92121

Main Phone: (858) 863-NEXT (6398)

www.nextval.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES